Everyone's IPF journey is unique, columnist Sam Kirton says, but that does not mean our experiences should become a competition.

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterized by an abnormal reepithelialisation, an excessive tissue remodelling and a progressive fibrosis within the ...

In the case of fibrotic pulmonary diseases such as idiopathic pulmonary fibrosis (IPF), the bleomycin model of lung injury in the mouse is widely used. To evaluate bleomycin-induced changes in the ...

providing detailed visuals of the pulmonary blood vessels in study case Showing A pulmonary embolism . The CT scan footage of Chest . The CT scan footage of Chest shows clear and well-defined lung ...

This important study describes a first-in-human trial of autologous p63+ stem cells in patients with idiopathic pulmonary fibrosis, a lethal condition for which effective treatments ... 24W P”.

its experimental therapy for serious lung disease idiopathic pulmonary fibrosis (IPF). The study will use the e-ILD platform to process high-resolution chest computed tomography (HRCT) images ...

Garadacimab is under clinical development by CSL and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 35% phase ...

Background: There is a paucity of real-world data on patients with interstitial lung diseases (ILDs) that are progressive, other than idiopathic pulmonary fibrosis (IPF), including treatment patterns ...

early inspiratory crackles and irreversible airflow obstruction by pulmonary function testing. Chest CT scans show a mosaic pattern, air trapping by the expiratory film, bronchiolectasis and ...

The current study suggests P63+ progenitor cell therapy is safe in patients with ILD. The authors attribute this to acquisition of cells from a healthy upper lobe site, removed from the lung fibrosis.